597645 The present disclosure discloses topical pharmaceutical formulations of berberine and its biologically equivalent analogues, such as jatrorrhizine, palmatine, coptisine, 9-demethylberberine, 9-demethylpalmatine, 13-hydroyberberine, berberrubine, palmatrubine, 9-O-ethylberberrubine, 9-O-ethyl-13-ethylberberrubine, 13-methyldihydroberberine N-methyl salt, tetrahydroprotoberberines and N-methyl salts thereof, and 9-lauroylberberrubine chloride, for the treatment of rosacea and other red face-related skin disorders. The topical pharmaceutical formulations of this invention contain purified berberine as the primary active drug ingredient at concentrations higher than 0.02%. The invention also discloses methods of treating rosacea and other red face related skin disorders, such as rosacea, acne vulgaris, seborrheic dermatitis, photodermatitis, contact dermatitis, steroid-induced rosacea-like dermatitis, and EGFR inhibitors-induced acneiform dermatitis, comprising the administration of topical pharmaceutical formulations according to the present disclosure.
